Aktionsplan PolyPid Ltd.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| IPO date |
2020-06-26 |
| ISIN |
IL0011326795 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.polypid.com
|
| Цена ао |
4.84 |
| Preisänderung pro Tag: |
+1.4% (2.85) |
| Preisänderung pro Woche: |
-10.25% (3.22) |
| Preisänderung pro Monat: |
-16.35% (3.455) |
| Preisänderung über 3 Monate: |
-20.17% (3.62) |
| Preisänderung über sechs Monate: |
-27.75% (4) |
| Preisänderung pro Jahr: |
-23.95% (3.8) |
| Preisänderung über 3 Jahre: |
-49.48% (5.72) |
| Preisänderung über 5 Jahre: |
0% (2.89) |
| Preisänderung über 10 Jahre: |
0% (2.89) |
| Preisänderung seit Jahresbeginn: |
-16.35% (3.455) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
0 |
0 |
| P/BV |
-2.42 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
-0.5341 |
0 |
| Gesamt: |
|
2.5 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
-155.25 |
0 |
| ROE, % |
1138.6 |
10 |
| Gesamt: |
|
3.33 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Gesamt: |
|
0 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
-0.519 |
10 |
| Gesamt: |
|
9.8 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
0 |
0 |
| Rentabilität Ebitda, % |
-30.61 |
0 |
| Rentabilität EPS, % |
-4857.39 |
0 |
| Gesamt: |
|
0 |
|
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Ms. Dikla Czaczkes Akselbrad |
CEO & Director |
347.88k |
1973 (52 Jahr) |
| Ms. Dalit Hazan |
Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs |
272.38k |
1971 (54 Jahr) |
| Mr. Ori Warshavsky |
Chief Operating Officer - US |
340.89k |
1978 (47 Jahre) |
| Mr. Jonny Missulawin |
Chief Financial Officer |
186.96k |
1987 (38 Jahre) |
| Ms. Maria Rubin |
Vice President of Operations |
N/A |
|
| Mr. Tal Vilnai |
General Counsel & Corporate Secretary |
N/A |
|
| Ms. Rivi Lev-ari |
Vice President of Human Resource |
N/A |
|
| Dr. Jean-Marc Hagai Pharm.D. |
Chief Commercial Officer |
N/A |
|
